--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-303512" form_type: "8-K" ticker: null cik: "0001811764" company_name: "POINT Biopharma Global Inc." filed_at: "2023-12-27T23:59:59+00:00" generated_at: "2026-06-07T06:59:31.401291+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 0.9 calibrated_materiality_score: 0.9 confidence: "high" source: SEC EDGAR --- # Lilly completes $12.50/share acquisition of POINT Biopharma; shares to be delisted ## Summary - Tender offer expired Dec 22; 72,788,215 shares (68%) validly tendered; Merger effective Dec 27. - Remaining shares converted into right to receive $12.50 per share in cash, less withholding. - Board replaced: Gordon Brooks, Phillip Johnson, Michael Thompson become directors; prior directors depart. - Company requests Nasdaq halt and delisting; plans to file Form 15 to terminate SEC reporting. - POINT Biopharma 2020 and 2021 equity incentive plans terminated effective at merger close. ## SEC filing metadata - accession: 0001193125-23-303512 - form_type: 8-K - cik: 0001811764 - company_name: POINT Biopharma Global Inc. - filed_at: 2023-12-27T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 0.9 - calibrated_materiality_score: 0.9 - confidence: high - sec_items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/d594310d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-303512 - JSON: https://secwatch.observer/filing/0001193125-23-303512.json - Plain text: https://secwatch.observer/filing/0001193125-23-303512.txt ## Key facts - Executive change Gerry Hogue departed as Director at POINT Biopharma Global Inc.. - Action: ceased - Role: Director source text: As of the Effective Time, Neil Fleshner, Jonathan Goodman, Gerry Hogue, David Lubner, Rajesh Malik, Bridget Martell, Yael Margolin, Joe McCann and Allan Silber each ceased to be directors of the Company and members of any committee of the Company’s board of directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Rajesh Malik departed as Director at POINT Biopharma Global Inc.. - Action: ceased - Role: Director source text: As of the Effective Time, Neil Fleshner, Jonathan Goodman, Gerry Hogue, David Lubner, Rajesh Malik, Bridget Martell, Yael Margolin, Joe McCann and Allan Silber each ceased to be directors of the Company and members of any committee of the Company’s board of directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Neil Fleshner departed as Director at POINT Biopharma Global Inc.. - Action: ceased - Role: Director source text: As of the Effective Time, Neil Fleshner, Jonathan Goodman, Gerry Hogue, David Lubner, Rajesh Malik, Bridget Martell, Yael Margolin, Joe McCann and Allan Silber each ceased to be directors of the Company and members of any committee of the Company’s board of directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Chris Anderson was appointed as Secretary at POINT Biopharma Global Inc.. - Action: appointed - Role: Secretary source text: The officers of Merger Sub immediately prior to the Effective Time were Philip L. Johnson as President, Chris Anderson as Secretary, Michael C. Thompson as Treasurer, Jonathan Groff as Assistant Secretary and Katie Lodato as Assistant Treasurer. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Philip L. Johnson was appointed as President at POINT Biopharma Global Inc.. - Action: appointed - Role: President source text: The officers of Merger Sub immediately prior to the Effective Time were Philip L. Johnson as President, Chris Anderson as Secretary, Michael C. Thompson as Treasurer, Jonathan Groff as Assistant Secretary and Katie Lodato as Assistant Treasurer. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Joe McCann departed as Director at POINT Biopharma Global Inc.. - Action: ceased - Role: Director source text: As of the Effective Time, Neil Fleshner, Jonathan Goodman, Gerry Hogue, David Lubner, Rajesh Malik, Bridget Martell, Yael Margolin, Joe McCann and Allan Silber each ceased to be directors of the Company and members of any committee of the Company’s board of directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Allan Silber departed as Director at POINT Biopharma Global Inc.. - Action: ceased - Role: Director source text: As of the Effective Time, Neil Fleshner, Jonathan Goodman, Gerry Hogue, David Lubner, Rajesh Malik, Bridget Martell, Yael Margolin, Joe McCann and Allan Silber each ceased to be directors of the Company and members of any committee of the Company’s board of directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Jonathan Goodman departed as Director at POINT Biopharma Global Inc.. - Action: ceased - Role: Director source text: As of the Effective Time, Neil Fleshner, Jonathan Goodman, Gerry Hogue, David Lubner, Rajesh Malik, Bridget Martell, Yael Margolin, Joe McCann and Allan Silber each ceased to be directors of the Company and members of any committee of the Company’s board of directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Phillip L. Johnson was appointed as Director at POINT Biopharma Global Inc.. - Action: appointed - Role: Director source text: The directors of Merger Sub immediately prior to the Effective Time were Gordon J. Brooks, Phillip L. Johnson and Michael C. Thompson. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Jonathan Groff was appointed as Assistant Secretary at POINT Biopharma Global Inc.. - Action: appointed - Role: Assistant Secretary source text: The officers of Merger Sub immediately prior to the Effective Time were Philip L. Johnson as President, Chris Anderson as Secretary, Michael C. Thompson as Treasurer, Jonathan Groff as Assistant Secretary and Katie Lodato as Assistant Treasurer. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Gordon J. Brooks was appointed as Director at POINT Biopharma Global Inc.. - Action: appointed - Role: Director source text: The directors of Merger Sub immediately prior to the Effective Time were Gordon J. Brooks, Phillip L. Johnson and Michael C. Thompson. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change David Lubner departed as Director at POINT Biopharma Global Inc.. - Action: ceased - Role: Director source text: As of the Effective Time, Neil Fleshner, Jonathan Goodman, Gerry Hogue, David Lubner, Rajesh Malik, Bridget Martell, Yael Margolin, Joe McCann and Allan Silber each ceased to be directors of the Company and members of any committee of the Company’s board of directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Michael C. Thompson was appointed as Director at POINT Biopharma Global Inc.. - Action: appointed - Role: Director source text: The directors of Merger Sub immediately prior to the Effective Time were Gordon J. Brooks, Phillip L. Johnson and Michael C. Thompson. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Bridget Martell departed as Director at POINT Biopharma Global Inc.. - Action: ceased - Role: Director source text: As of the Effective Time, Neil Fleshner, Jonathan Goodman, Gerry Hogue, David Lubner, Rajesh Malik, Bridget Martell, Yael Margolin, Joe McCann and Allan Silber each ceased to be directors of the Company and members of any committee of the Company’s board of directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Katie Lodato was appointed as Assistant Treasurer at POINT Biopharma Global Inc.. - Action: appointed - Role: Assistant Treasurer source text: The officers of Merger Sub immediately prior to the Effective Time were Philip L. Johnson as President, Chris Anderson as Secretary, Michael C. Thompson as Treasurer, Jonathan Groff as Assistant Secretary and Katie Lodato as Assistant Treasurer. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Michael C. Thompson was appointed as Treasurer at POINT Biopharma Global Inc.. - Action: appointed - Role: Treasurer source text: The officers of Merger Sub immediately prior to the Effective Time were Philip L. Johnson as President, Chris Anderson as Secretary, Michael C. Thompson as Treasurer, Jonathan Groff as Assistant Secretary and Katie Lodato as Assistant Treasurer. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Executive change Yael Margolin departed as Director at POINT Biopharma Global Inc.. - Action: ceased - Role: Director source text: As of the Effective Time, Neil Fleshner, Jonathan Goodman, Gerry Hogue, David Lubner, Rajesh Malik, Bridget Martell, Yael Margolin, Joe McCann and Allan Silber each ceased to be directors of the Company and members of any committee of the Company’s board of directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Governance Changes POINT Biopharma Global Inc.: Amended and restated certificate of incorporation in connection with merger. - Change: charter amendment source text: the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - Governance Changes POINT Biopharma Global Inc.: Amended and restated bylaws effective at merger close. - Change: bylaw amendment source text: the by-laws of Merger Sub immediately prior to the Effective Time became the by-laws of the Company effective as of the Effective Time evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm - M&A Transactions POINT Biopharma Global Inc. underwent a change of control involving Eli Lilly and Company for $12.50 per share in cash (closed 2023-12-27). - Action: change of control - Counterparty: Eli Lilly and Company - Consideration: $12.50 per share in cash - Closing: 2023-12-27 source text: a cash tender offer (the “ Offer ”) to purchase all of the outstanding shares of common stock of the Company, par value $0.0001 per share (the “ Shares ”), at a price of $12.50 per share (the “ Offer Price ”), net to the seller in cash, without interest, subject to applicable withholding taxes and on the terms and subject to the conditions set forth in evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.